DAJY(SZ:002030) Xin Lang Cai Jing·2025-10-31 01:28Core Insights - The company, DaAn Gene (002030.SZ), reported a total revenue of 504 million yuan for Q3 2025, with a net profit attributable to shareholders of -142 million yuan, an increase of 361 million yuan compared to the same period last year [1] Financial Performance - The company's latest asset-liability ratio stands at 12.09%, ranking 32nd among disclosed peers, with a decrease of 0.66 percentage points from the previous quarter and a decrease of 1.76 percentage points from the same period last year [3] - The latest gross profit margin is 32.67%, while the return on equity (ROE) is -1.83%, which is an increase of 4.21 percentage points compared to the same period last year [3] - The diluted earnings per share are -0.10 yuan, an increase of 0.26 yuan compared to the same period last year [3] - The total asset turnover ratio is 0.05 times, and the inventory turnover ratio is 1.73 times, ranking 49th among disclosed peers, with an increase of 0.24 times from the same period last year, representing a year-on-year increase of 16.41% [3] Shareholder Structure - The number of shareholders is 140,900, with the top ten shareholders holding a total of 512 million shares, accounting for 36.45% of the total share capital [3] - The top ten shareholders and their respective holdings are as follows: 1. Guangzhou Guangyong Technology Development Co., Ltd. - 16.6% 2. Guangzhou Biomedicine and Health Industry Investment Co., Ltd. - 10.00% 3. Guangzhou Financial Holdings Group Co., Ltd. - 5.00% 4. He Yunshao - 1.82% 5. Central Huijin Asset Management Co., Ltd. - 0.91% 6. Hong Kong Central Clearing Limited - 0.79% 7. China Merchants Bank Co., Ltd. - 0.43% 8. Shi Jingbo - 0.37% 9. Xu Tai - 0.29% 10. Wu Weike - 0.20% [3]